| 缩写名/全名 |
MOL CANCER THER
MOLECULAR CANCER THERAPEUTICS |
||||||||||||||||||||
| ISSN号 | 1535-7163 | ||||||||||||||||||||
| 研究方向 | 医学-肿瘤学 | ||||||||||||||||||||
| 影响因子 | 2015:5.579, 2016:5.764, 2017:5.365, 2018:4.856, 2019:5.615, | ||||||||||||||||||||
| 出版国家 | UNITED STATES | ||||||||||||||||||||
| 出版周期 | Monthly | ||||||||||||||||||||
| 年文章数 | 217 | ||||||||||||||||||||
| 出版年份 | 2001 | ||||||||||||||||||||
| 是否OA | No | ||||||||||||||||||||
| 审稿周期(仅供参考) | 平均3月 |
||||||||||||||||||||
| 录用比例 | 约50% | ||||||||||||||||||||
| 投稿链接 | http://mct.msubmit.net/cgi-bin/main.plex | ||||||||||||||||||||
| 投稿官网 | http://mct.aacrjournals.org/ | ||||||||||||||||||||
| h-index | 157 | ||||||||||||||||||||
| CiteScore |
|
||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D | ||||||||||||||||||||
| 中科院SCI期刊分区 （ 2018年新版本） |
|
||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年新版本） |
|
| 中国学者近期发表的论文 | |
| 1. | Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. Author: Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X, Chen X, Ma S. Journal: Mol Cancer Ther. 2016 May;15(5):842-53. doi: 10.1158/1535-7163.MCT-15-0445. Epub 2016 Feb 2. PubMed |
| 2. | Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption. Author: Xu L, Luo J, Jin R, Yue Z, Sun P, Yang Z, Yang X, Wan W, Zhang J, Li S, Liu M, Xiao J. Journal: Mol Cancer Ther. 2016 May;15(5):854-65. doi: 10.1158/1535-7163.MCT-15-0669. Epub 2016 Feb 9. PubMed |
| 3. | Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Author: Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN. Journal: Mol Cancer Ther. 2016 Apr;15(4):574-82. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16. PubMed |
| 4. | Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression. Author: Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX. Journal: Mol Cancer Ther. 2016 May;15(5):1082-94. doi: 10.1158/1535-7163.MCT-15-0707. Epub 2016 Feb 23. PubMed |
| 5. | Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis. Author: Yang J, Qian S, Cai X, Lu W, Hu C, Sun X, Yang Y, Yu Q, Gao SP, Cao P. Journal: Mol Cancer Ther. 2016 Jun;15(6):1190-200. doi: 10.1158/1535-7163.MCT-15-0551. Epub 2016 Feb 29. PubMed |
| 6. | Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Author: Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR, Hill R. Journal: Mol Cancer Ther. 2016 May;15(5):1043-52. doi: 10.1158/1535-7163.MCT-15-0774. Epub 2016 Mar 3. PubMed |
| 7. | BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer. Author: Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang M, Wang L, Luo G, Li Y, Zeng F, Jiang G. Journal: Mol Cancer Ther. 2016 May;15(5):1029-42. doi: 10.1158/1535-7163.MCT-15-0750. Epub 2016 Mar 3. PubMed |
| 8. | Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Author: Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Journal: Mol Cancer Ther. 2016 Apr;15(4):731-42. doi: 10.1158/1535-7163.MCT-15-0706. Epub 2016 Mar 3. PubMed |
| 9. | RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Author: Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P. Journal: Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1. PubMed |
| 10. | Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma. Author: Du Z, Caenepeel S, Shen Y, Rex K, Zhang Y, He Y, Tang ET, Wang O, Zhong W, Zhou H, Huang J, Huang E, Hu L, Coxon A, Zhang M. Journal: Mol Cancer Ther. 2016 Jun;15(6):1227-37. doi: 10.1158/1535-7163.MCT-15-0745. Epub 2016 Mar 29. PubMed |
|
|
